Biomed & Biotech Firms - Publicly Traded*

Receptos Inc.

3033 Science Park Rd. Ste., 300
San Diego, CA 92121

Company Est.:

Year Est. in San Diego: 2009

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Receptos Inc.

Market Cap as of 6/12/2015


Market Cap as of 7/03/2014

Market Cap as of 07/02/2013

Market Cap as of 06/26/2012

Market Cap as of 01/04/2012

Market Cap as of 06/20/2011

Market Cap as of 01/06/2011

Exchange and Ticker Symbol


Fields of Research

Receptos has an active research program for glucagon-like peptide-1 receptor (GLP-1R) small molecule positive allosteric modulators (PAMs) for the treatment of type 2 diabetes mellitus (T2D).
GLP-1R peptide agonists are an effective therapeutic option for the treatment of T2D in terms of controlling glucose as well as causing weight loss

Major Products



FAheem Hasnain

  • Chief Executive Officer
  • President